Comparing six cardiovascular risk prediction models in Haiti: implications for identifying high-risk individuals for primary prevention

Lily D Yan, Jean Lookens Pierre, Vanessa Rouzier, Michel Théard, Alexandra Apollon, Stephano St Preux, Justin R Kingery, Kenneth A Jamerson, Marie Deschamps, Jean W Pape, Monika M Safford, Margaret L McNairy, Lily D Yan, Jean Lookens Pierre, Vanessa Rouzier, Michel Théard, Alexandra Apollon, Stephano St Preux, Justin R Kingery, Kenneth A Jamerson, Marie Deschamps, Jean W Pape, Monika M Safford, Margaret L McNairy

Abstract

Background: Cardiovascular diseases (CVD) are rapidly increasing in low-middle income countries (LMICs). Accurate risk assessment is essential to reduce premature CVD by targeting primary prevention and risk factor treatment among high-risk groups. Available CVD risk prediction models are built on predominantly Caucasian risk profiles from high-income country populations, and have not been evaluated in LMIC populations. We aimed to compare six existing models for predicted 10-year risk of CVD and identify high-risk groups for targeted prevention and treatment in Haiti.

Methods: We used cross-sectional data within the Haiti CVD Cohort Study, including 1345 adults ≥ 40 years without known history of CVD and with complete data. Six CVD risk prediction models were compared: pooled cohort equations (PCE), adjusted PCE with updated cohorts, Framingham CVD Lipids, Framingham CVD Body Mass Index (BMI), WHO Lipids, and WHO BMI. Risk factors were measured during clinical exams. Primary outcome was continuous and categorical predicted 10-year CVD risk. Secondary outcome was statin eligibility.

Results: Sixty percent were female, 66.8% lived on a daily income of ≤ 1 USD, 52.9% had hypertension, 14.9% had hypercholesterolemia, 7.8% had diabetes mellitus, 4.0% were current smokers, and 2.5% had HIV. Predicted 10-year CVD risk ranged from 3.6% in adjusted PCE (IQR 1.7-8.2) to 9.6% in Framingham-BMI (IQR 4.9-18.0), and Spearman rank correlation coefficients ranged from 0.86 to 0.98. The percent of the cohort categorized as high risk using model specific thresholds ranged from 1.8% using the WHO-BMI model to 41.4% in the PCE model (χ2 = 1416, p value < 0.001). Statin eligibility also varied widely.

Conclusions: In the Haiti CVD Cohort, there was substantial variation in the proportion identified as high-risk and statin eligible using existing models, leading to very different treatment recommendations and public health implications depending on which prediction model is chosen. There is a need to design and validate CVD risk prediction tools for low-middle income countries that include locally relevant risk factors.

Trial registration: clinicaltrials.gov NCT03892265 .

Keywords: Cardiovascular diseases; Cardiovascular Risk; Global health; Hypertension; Primary prevention.

Conflict of interest statement

JLP, VR, JWP, MLM report a grant from NHLBI R01HL143788. The remaining authors declare they have no conflicts of interest.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Predicted 10-year CVD risk categorizations by model. Legend: Figure shows proportion of cohort categorized as low, intermediate, or high-risk. Panel A uses a uniform threholds for low, intermediate, and high-risk: 

References

    1. GBD 2017 Causes of Death Collaborators Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736–88. doi: 10.1016/S0140-6736(18)32203-7.
    1. GBD 2017 Risk Factor Collaborators Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1923–94. doi: 10.1016/S0140-6736(18)32225-6.
    1. Robert B, Srinath R, Leeder Stephen R. Poverty and human development. Circulation. 2007;116(17):1871–1873. doi: 10.1161/CIRCULATIONAHA.107.736926.
    1. Yan LD, Rouzier V, Pierre JL, Lee MH, Muntner P, Parsons PJ, et al. High lead exposure associated with higher blood pressure in Haiti: a warning sign for low-income countries. Hypertension (Dallas, Tex.: 1979) 79, no. 1 (January 2022): 283–90. 10.1161/HYPERTENSIONAHA.121.18250.
    1. GBD Compare. IHME Viz Hub. [cited 2021 Jan 22]. Available from:
    1. Feigin VL, Brainin M, Norrving B, Gorelick PB, Dichgans M, Wang W, et al. What is the best mix of population-wide and high-risk targeted strategies of primary stroke and cardiovascular disease prevention? J Am Heart Assoc. 2020;9(3):e014494. doi: 10.1161/JAHA.119.014494.
    1. NCD Management-Screening, Diagnosis and Treatment. HEARTS Technical Package . WHO; 2018 Jun [cited 2021 Jan 7]. Available from:
    1. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73.
    1. D’Agostino RB, Ramachandran VS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(6):743–753. doi: 10.1161/CIRCULATIONAHA.107.699579.
    1. Kaptoge S, Pennells L, Bacquer DD, Cooney MT, Kavousi M, Stevens G, et al. World health organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332–e1345. doi: 10.1016/S2214-109X(19)30318-3.
    1. Lookens J, Tymejczyk O, Rouzier V, Smith C, Preval F, Joseph I, et al. The Haiti cardiovascular disease cohort: study protocol for a population-based longitudinal cohort. BMC Public Health. 2020;20:1. doi: 10.1186/s12889-020-09734-x.
    1. WHO . WHO STEPS surveillance manual: The WHO STEPwise approach to chronic disease risk factor surveillance. Geneva: WHO; 2017.
    1. Agarwal R. Implications of blood pressure measurement technique for implementation of Systolic Blood Pressure Intervention Trial (SPRINT) J Am Heart Assoc. 2017;6(2):e004536. doi: 10.1161/JAHA.116.004536.
    1. Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min Y-I, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. 2018;169(1):20. doi: 10.7326/M17-3011.
    1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–e1143.
    1. National Cholesterol Education Program (NCEP) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421. doi: 10.1161/circ.106.25.3143.
    1. Haitian Institute of Childhood (IHE), ICF . Mortality, morbidity and the utilization Survey (EMMUS-VI 2016-2017) Pétion-Ville, Haiti and Rockville, Maryland, USA: IHE and ICF; 2018.
    1. Guerra-Silva NMM, Santucci FS, Moreira RC, Tashima CM, de Melo SCCS, Pereira LRL, et al. Coronary disease risk assessment in men: comparison between ASCVD risk versus framingham. Int J Cardiol. 2017;1(228):481–487. doi: 10.1016/j.ijcard.2016.11.102.
    1. Garg N, Muduli SK, Kapoor A, Tewari S, Kumar S, Khanna R, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J. 2017;69(4):458–463. doi: 10.1016/j.ihj.2017.01.015.
    1. Mosepele M, Hemphill LC, Palai T, Nkele I, Bennett K, Lockman S, et al. Cardiovascular disease risk prediction by the American College of Cardiology (ACC)/American Heart Association (AHA) Atherosclerotic Cardiovascular Disease (ASCVD) risk score among HIV-infected patients in sub-Saharan Africa. PLoS One. 2017;12(2):e0172897. doi: 10.1371/journal.pone.0172897.
    1. Motamed N, Rabiee B, Perumal D, Poustchi H, Miresmail SJH, Farahani B, et al. Comparison of cardiovascular risk assessment tools and their guidelines in evaluation of 10-year CVD risk and preventive recommendations: a population based study. Int J Cardiol. 2017;1(228):52–57. doi: 10.1016/j.ijcard.2016.11.048.
    1. Kakadiaris IA, Vrigkas M, Yen AA, Kuznetsova T, Budoff M, Naghavi M. Machine learning outperforms ACC/AHA CVD risk calculator in MESA. J Am Heart Assoc. 2018;7:e009476. doi: 10.1161/JAHA.118.009476.
    1. Kwan GF, Mayosi BM, Mocumbi AO, Miranda JJ, Ezzati M, Jain Y, et al. Endemic cardiovascular diseases of the poorest billion. Circulation. 2016;133(24):2561–2575. doi: 10.1161/CIRCULATIONAHA.116.008731.
    1. Mendis S, Al Bashir I, Dissanayake L, Varghese C, Fadhil I, Marhe E, et al. Gaps in capacity in primary care in low-resource settings for implementation of essential noncommunicable disease interventions. Int J Hypertens. 2012;2012:584041. doi: 10.1155/2012/584041.
    1. Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability. J Am Heart Assoc. 2020;9(9):e015302. doi: 10.1161/JAHA.119.015302.
    1. Joseph FJ-J. LISTE NATIONALE DES MÉDICAMENTS ESSENTIELS. Direction de la Pharmacie, du Médicamentet de la Médecine Traditionnelle; 2012 May p. 74.
    1. Chahal HS, St. Fort N, Bero L. Availability, prices and affordability of essential medicines in Haiti. J Glob Health. 2013;3(2):020405. doi: 10.7189/jogh.03.020405.
    1. Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, et al. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Global Health. 2020;5(11):e002640. doi: 10.1136/bmjgh-2020-002640.

Source: PubMed

Подписаться